Pre-Submission Review for Nephrology Papers

Nephrology reviewers often ask:

• is the kidney disease phenotype defined precisely?
• are CKD stage, AKI definition, proteinuria, eGFR, dialysis status, transplant status, pathology, and comorbidities clear?
• are renal endpoints clinically meaningful and mature enough?
• does the analysis handle competing risk, missingness, treatment changes, and baseline kidney function?
• does the mechanism explain kidney disease or only correlate with kidney markers?
• are trial registration, reporting checklists, data statements, and ethics complete?
• does the paper fit Kidney International, JASN, NDT, Kidney International Reports, CJASN, or a disease-specific venue?

The target should match the renal contribution, not only the presence of a kidney variable.

In our pre-submission review work, nephrology manuscripts most often fail when the kidney phenotype or endpoint is not specific enough for the journal's evidence bar.

Phenotype blur: CKD, AKI, glomerular disease, transplant, dialysis, or biomarker cohorts are combined without a clear renal rationale.

Endpoint mismatch: eGFR slope, proteinuria, creatinine, dialysis initiation, graft loss, or composite outcomes are interpreted more broadly than the design supports.

Mechanism-to-disease gap: mechanistic data are interesting but not tied clearly to human kidney disease, disease stage, or pathology.

Treatment-context gap: RAAS blockade, SGLT2 inhibitors, immunosuppression, dialysis modality, or transplant medications are not handled clearly.

Subgroup overclaim: small disease subgroups, pathology classes, or treatment strata carry conclusions that the study cannot support.

A useful review should identify the first kidney-specific objection a nephrology reviewer would raise.

Kidney International guide-for-authors materials include reporting guideline expectations, ICMJE data-sharing statement policy for clinical trials, and a requirement for a data availability statement. Journal of Nephrology author guidance similarly points to data availability statements and CONSORT compliance for randomized clinical trials. Nephrology Dialysis Transplantation guidance lists data availability, author contributions, funding, and conflict statements among required manuscript elements.

Those signals make nephrology readiness partly clinical, partly mechanistic, and partly reporting discipline.

Send the manuscript, target journal, protocol, reporting checklist, disease definitions, endpoint definitions, baseline kidney-function table, medication and treatment context, pathology or biopsy criteria if relevant, statistical analysis plan, data availability statement, figures, supplement, and prior reviewer comments if available.

If the paper involves dialysis or transplant, include modality, vintage, immunosuppression, donor and recipient context, access type, or graft-function definitions as appropriate.

A useful nephrology pre-submission review should include:

• kidney-claim verdict
• phenotype and endpoint critique
• treatment and disease-stage context review
• mechanism-to-disease check
• statistics and subgroup review
• reporting-guideline and data-statement check
• journal-lane recommendation
• submit, revise, retarget, or diagnose deeper call

The review should not only say "clarify renal relevance." It should identify which kidney-specific detail controls the editorial decision.

Before submission, authors often need to:

• sharpen CKD, AKI, transplant, dialysis, or pathology definitions
• clarify endpoint hierarchy and clinical meaning
• separate exploratory biomarker claims from clinical conclusions
• add baseline kidney function, medication, and treatment context
• address competing risks, missingness, and subgroup limitations
• connect mechanism to kidney disease stage or pathology
• complete reporting and data availability requirements
• retarget from a flagship nephrology journal to a specialty kidney, transplant, dialysis, hypertension, or clinical venue

These fixes prevent a kidney paper from sounding more mature or generalizable than it is.

A CKD paper needs staging, eGFR trajectory, proteinuria, comorbidities, and treatment context. An AKI paper needs definition, timing, severity, recovery, and competing risks. A glomerular disease paper needs pathology, treatment, relapse, remission, and proteinuria context. A transplant paper needs donor and recipient context, immunosuppression, graft outcomes, rejection definitions, and follow-up. A dialysis paper needs modality, access, vintage, adequacy, complications, and patient selection. A biomarker paper needs validation, clinical utility, and incremental value beyond standard renal measures.

The AI manuscript review can flag whether the blocking risk is phenotype, endpoint maturity, mechanism, statistics, or journal fit.

Use this page when the manuscript's submission risk depends on kidney phenotype, renal endpoints, nephrology mechanisms, dialysis, transplant, kidney pathology, or nephrology journal targeting. Use medical manuscript review when kidney outcomes are secondary and the main paper is broader clinical medicine.

That distinction keeps the page focused on the nephrology buyer's actual problem.

Do not submit a nephrology paper if the kidney phenotype, disease stage, and endpoint definitions are still loose. A reviewer should not have to infer whether the paper is about CKD progression, acute injury, renal recovery, graft outcome, dialysis management, or kidney-disease mechanism.

Also pause if a biomarker or mechanism is presented as clinically useful without showing what it adds beyond existing renal measures. Nephrology reviewers will ask whether the marker changes risk prediction, treatment selection, mechanism understanding, or patient management.

For dialysis and transplant manuscripts, pause again if selection and treatment context are underdescribed. The same result can mean different things depending on modality, access, vintage, immunosuppression, donor factors, or baseline risk.

For cardiorenal or diabetes-kidney papers, pause if the manuscript does not name which field owns the primary claim. A paper can speak to multiple specialties, but the abstract should make clear whether the main audience is nephrology, cardiology, endocrinology, or general medicine.